TDP-43-storing cell model
Disclosed is a transformed cell (a cell model) which can form a cytoplasmic inclusion body derived from TAR DNA-binding protein of 43 kDa (TDP-43) that is found in the brain of a patient suffering from a neurodegenerative disease such as FTLD and ALS. The transformed cell is characterized by having, introduced therein, a promoter capable of functioning in a host cell and a mutant TDP-43 gene.
1. A transformed cell having a mutant TDP-43 gene operably linked to a promoter introduced therein, wherein the mutant TDP-43 gene encodes any one of the following proteins (a) to (c):
(a) a protein having an amino acid sequence obtained by deleting amino acids 187-192 from the amino acid sequence of wild-type TDP-43;
(b) a protein having an amino acid sequence obtained by deleting amino acids 78-84 and amino acids 187-192 from the amino acid sequence of wild-type TDP-43; and
(c) a protein that has an amino acid sequence having one to ten amino acids deleted from, substituted in or added to the amino acid sequence (a) or (b), and that has an activity of forming an intracellular inclusion.
2. The cell according to claim 1 , wherein the mutant TDP-43 has no CFTR exon 9 skipping activity.
3. The cell according to claim 1 , which is a transformed mammal cell.
4. The cell according to claim 3 , wherein the mammal cell is a central nervous system cell, a peripheral nervous system cell or a neuroblast.
5. A method for screening a therapeutic drug for a neurodegenerative disease, comprising the steps of: causing the cell according to claim 1 to make contact with a candidate substance to measure a cellular activity of the cell; and using the obtained measurement result as an indicator.
6. The method according to claim 5 , wherein the cellular activity is at least one selected from the group consisting of proliferation capacity, viability, and the rate, number and size of an intracellular mutant TDP-43 inclusion formed.
7. The method according to claim 5 or 6 , wherein the neurodegenerative disease is frontotemporal lobar degeneration or amyotrophic lateral sclerosis.
8. The method according to claim 5 , wherein the neurodegenerative disease is associated with formation of an intracellular TDP-43 inclusion.
9. A method for screening an agent for suppressing formation of an intracellular mutant TDP-43 inclusion, comprising the steps of: causing the cell according to claim 1 to make contact with a candidate substance to measure a cellular activity of the cell; and using the obtained measurement result as an indicator.
10. The method according to claim 9 , wherein the cellular activity is at least one selected from the group consisting of proliferation capacity, viability, and the rate, number and size of an intracellular mutant TDP-43 inclusion formed.
11. A method for assessing a side-effect of a therapeutic drug for a neurodegenerative disease, comprising the steps of: causing the cell according to claim 1 to make contact with the therapeutic drug for the neurodegenerative disease to measure a cellular activity of the cell: and using the obtained measurement result as an indicator.
12. The method according to claim 11 , wherein the cellular activity is at least one selected from the group consisting of neurite elongation capability, proliferation capacity and viability.
13. The method according to claim 11 or 12 , wherein the neurodegenerative disease is frontotemporal lobar degeneration or amyotrophic lateral sclerosis.
14. The method according to claim 11 , wherein the neurodegenerative disease is associated with formation of an intracellular TDP-43 inclusion.